Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats

Synapse

Volumn 47, Issue 3, 2003, Pages 176-183

  Le Foll, Bernard ^a   Diaz, Jorge ^b   Sokoloff, Pierre ^a  

^a CENTRE PAUL BROCA   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cigarette smoking; Nucleus accumbens shell; Preprodynorphin; Preprotachykinin

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; LEVODOPA; MESSENGER RNA; NICOTINE; PREPRODYNORPHIN; PREPROTACHYKININ; SODIUM CHLORIDE; DRD3 PROTEIN, RAT; DYNORPHIN; PRE PRODYNORPHIN; PRE-PRODYNORPHIN; PROTEIN PRECURSOR; TACHYKININ;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; IN SITU HYBRIDIZATION; LOCOMOTION; MESOLIMBIC DOPAMINERGIC SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BINDING; SENSITIZATION; SMOKING HABIT; ANIMAL; BIOSYNTHESIS; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION; GENETICS; MALE; METABOLISM; MOTOR ACTIVITY; SPRAGUE DAWLEY RAT;

ANIMALS; AUTORADIOGRAPHY; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DYNORPHINS; GENE EXPRESSION; IN SITU HYBRIDIZATION; MALE; MOTOR ACTIVITY; NICOTINE; NUCLEUS ACCUMBENS; PROTEIN PRECURSORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RNA, MESSENGER; TACHYKININS;

EID: 0037332633     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10170     Document Type: Article

References (70)

1. Anderson KD, Reiner A. 1990. Extensive co-occurrence of substance P and dynorphin in striatal projection neurons: an evolutionarily conserved feature of basal ganglia organization. J Comp Neurol 295:339-369.
2. Balfour DJ, Wright AE, Benwell ME, Birrell CE. 2000. The putative role of extra-synaptic mesolimbic dopamine in the neurobiology of nicotine dependence. Behav Brain Res 113:73-83.
3. Benwell ME, Balfour DJ. 1992. The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br J Pharmacol 105:849-856.
4. Birrell CE, Balfour DJ. 1998. The influence of nicotine pretreatment on mesoaccumbens dopamine overflow and locomotor responses to D-amphetamine. Psychopharmacology (Berl) 140:142-149.
5. 3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 94:3363-3367.
6. Bordet R, Ridray S, Schwartz J-C, Sokoloff P. 2000. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur J Neurosci 12:2117-123.
7. 2 receptor mRNA. Brain Res 564:203-219.
8. Burris KD, Filtz TM, Chumpradit S, Kung MP, Foulon C, Hensler JG, Kung HF, Molinoff PB. 1994. Characterization of 125I R trans 7-OH-PIPAT binding to dopamine D3 receptors in rat olfactory tubercule. J Pharmacol Exp Ther 268:935-942.
9. Cadoni C, Di Chiara G. 2000. Differential changes in accumbens shell and core dopamine in behavioral sensitization to nicotine. Eur J Pharmacol 387:R23-25.
10. 3 dopamine receptors. Science 260:1814-1816.
11. Caine SB, Koob GF, Parsons LH, Everitt BJ, Schwartz J-C, Sokoloff P. 1997. D3 receptor functional test in vitro predicts potencies of dopamine agonists to reduce cocaine self-administration. Neuroreport 8:2373-2377.
12. Carr LA, Rowell PP, Pierce Jr WM. 1989. Effects of subchronic nicotine administration on central dopaminergic mechanisms in the rat. Neurochem Res 14:511-15.
13. Clarke PB. 1987. Nicotine and smoking: a perspective from animal studies. Psychopharmacology (Berl) 92:135-143.
14. Clarke PB, Kumar R. 1983a. Characterization of the locomotor stimulant action of nicotine in tolerant rats. Br J Pharmacol 80:587-594.
15. Clarke PB, Kumar R. 1983b. The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. Br J Pharmacol 78:329-337.
16. Clarke PB, Fu DS, Jakubovic A, Fibiger HC. 1988. Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J Pharmacol Exp Ther 246:701-708.
17. Corrigall WA, Coen KM. 1991. Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology (Berl) 104:171-176.
18. Court JA, Lloyd S, Thomas N, Piggott MA, Marshall EF, Morris CM, Lamb H, Perry RH, Johnson M, Perry EK. 1998. Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. Neuroscience 87:63-78.
19. Cox BM, Goldstein A, Nelson WT. 1984. Nicotine self-administration in rats. Br J Pharmacol 83:49-55.
20. 3 receptor. Neuroscience 65:731-745.
21. Diaz J, Pilon C, Le Foll B, Gros C, Triller A, Schwartz JC, Sokoloff P. 2000. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci 20:8677-8684.
22. Domino EF. 2001. Nicotine induced behavioral locomotor sensitization. Prog Neuropsychopharmacol Biol Psychiatry 25:59-71.
23. Domino EF, Lutz MP. 1973. Tolerance to the effects of daily nicotine on rat bar pressing behavior for water reinforcement. Pharmacol Biochem Behav 1:445-448.
24. Fung YK. 1989. Effects of chronic nicotine pretreatment on (+)-amphetamine and nicotine-induced synthesis and release of [3H]dopamine from [3H]tyrosine in rat nucleus accumbens. J Pharm Pharmacol 41:66-68.
25. Fung YK, Lau YS. 1992. Chronic effects of nicotine on mesolimbic dopaminergic system in rats. Pharmacol Biochem Behav 41:57-63.
26. Fung YK, Schmid MJ, Anderson TM, Lau YS. 1996. Effects of nicotine withdrawal on central dopaminergic systems. Pharmacol Biochem Behav 53:635-640.
27. Glassman AH. 1993. Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 150:546-553.
28. Goldberg SR, Spealman RD, Goldberg DM. 1981. Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science 214:573-557.
29. Grenhoff J, Aston-Jones G, Svensson TH. 1986. Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol Scand 128:351-358.
30. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. 2001. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411:86-89.
31. 3 receptors and use of antipsychotics in patients with schizophrenia. Arch Gen Psychiatry 54:225-232.
32. Henningfield JE, Goldberg SR. 1983. Control of behavior by intravenous nicotine injections in human subjects. Pharmacol Biochem Behav 19:1021-1026.
33. Herrera-Marschitz M, Ungerstedt U. 1986. Striato-nigral dynorphin and substance P pathways in the rat. Exp Brain Res 64:193-207.
34. Horger BA, Iyasere CA, Berhow MT, Messer CJ, Nestler EJ, Taylor JR. 1999. Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. J Neurosci 19:4110-4122.
35. Imperato A, Mulas A, Di Chiara G. 1986. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 132:337-338.
36. Janson AM, Hedlund PB, Hillefors M, von Euler G. 1992. Chronic nicotine treatment decreases dopamine D2 agonist binding in the rat basal ganglia. Neuroreport 3:1117-1120.
37. Kalivas PW, Stewart J. 1991. Dopamine transmission in the initition and expression of drug- and stress-induced sensitization of motor activity. Brain Res Rev 16:223-244.
38. Kirch DG, Taylor TR, Creese I, Xu SX, Wyatt RJ. 1992. Effect of chronic nicotine treatment and withdrawal on rat striatal D1 and D2 dopamine receptors. J Pharm Pharmacol 44:89-92.
39. Ksir C. 1994. Acute and chronic nicotine effects on measures of activity in rats: a multivariate analysis. Psychopharmacology (Berl) 115:105-109.
40. Ksir C, Hakan RL, Kellar KJ. 1987. Chronic nicotine and locomotor activity: influences of exposure dose and test dose. Psychopharmacology (Berl) 92:25-29.
41. 3 receptor agents as potential new medications for drug addiction. Eur Psychiatry 15:140-146.
42. 3 receptor in reactivity to cocaine-associated cues in mice. Eur J Neurosci 15:2016-2026.
43. 2 dopamine receptors. Neuroscience 73:131-143.
44. 3H]-hydroxy-N,N di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA 89:8155-8159.
45. 3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc Natl Acad Sci USA 92:1719-1723.
46. Mathieu AM, Caboche J, Besson MJ. 1996. Distribution of preproenkephalin, preprotachykinin A, and preprodynorphin mRNAs in the rat nucleus accumbens: effect of repeated administration of nicotine. Synapse 23:94-106.
47. Mathieu-Kia AM, Besson MJ. 1998. Repeated administration of cocaine, nicotine and ethanol: effects on preprodynorphin, preprotachykinin A and preproenkephalin mRNA expression in the dorsal and the ventral striatum of the rat. Brain Res Mol Brain Res 54:141-151.
48. Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Dubuffet T, Lavielle G. 2000. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors. I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 293:1048-1062.
49. Morrison CF. 1967. Effects of nicotine on operant behaviour of rats. Int J Neuropharmacol 6:229-240.
50. Morrison CF, Stephenson JA. 1972. The occurrence of tolerance to a central depressant effect of nicotine. Br J Pharmacol 46:151-156.
51. Nisell M, Nomikos GG, Hertel P, Panagis G, Svensson TH. 1996. Condition-independent sensitization of locomotor stimulation and mesocortical dopamine release following chronic nicotine treatment in the rat. Synapse 22:369-381.
52. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. 1997. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390:401-404.
53. Pietila K, Salminen O, Leikola-Pelho T, Ahtee L. 1996. Tolerance to nicotine's effects on striatal dopamine metabolism in nicotine-withdrawn mice. Eur J Pharmacol 318:17-22.
54. 3 receptor agonist. Nature 400:371-375.
55. Pontieri FE, Tanda G, Orzi F, Di Chiara G. 1996. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382:255-257
56. Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, Hadley MS, Hunter AJ, Jeffrey P, Jewitt F, Johnson CN, Jones DN, Medhurst AD, Middlemiss DN, Nash DJ, Riley GJ, Routledge C, Stemp G, Thewlis KM, Trail B, Vong AK, Hagan JJ. 2000. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294:1154-1165.
57. Reilly MA, Lapin EP, Maker HS, Lajtha A. 1987. Chronic nicotine administration increases binding of [3H]domperidone in rat nucleus accumbens. J Neurosci Res 18:621-625.
58. 3 receptors in rat ventral striatum: opposite and synergistic functional interactions. Eur J Neurosci 10:1676-1686.
59. Robinson TE, Berridge KC. 1993. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 18:247-291.
60. Robinson TE, Berridge KC. 2001. Incentive-sensitization and addiction. Addiction 96:103-114.
61. Rodgers RJ. 1979. Effects of nicotine, mecamylamine, and hexamethonium on shock-induced fighting, pain reactivity, and locomotor behaviour in rats. Psychopharmacology (Berl) 66:93-98.
62. Rosecrans JA, Stimler CA, Hendry JS, Meltzer LT. 1989. Nicotine-induced tolerance and dependence in rats and mice: studies involving schedule-controlled behavior. Prog Brain Res 79:239-248.
63. 3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Mol Brain Res 45:335-339.
64. Shoaib M, Benwell ME, Akbar MT, Stolerman IP, Balfour DJ. 1994. Behavioural and neurochemical adaptations to nicotine in rats: influence of NMDA antagonists. Br J Pharmacol 111:1073-1080.
65. 3) as a target for neuroleptics. Nature 347:146-151.
66. Staley JK, Mash DC. 1996. Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J. Neurosci 16:6100-6106.
67. Suemaru K, Gomita Y, Furuno K, Araki Y. 1993. Chronic nicotine treatment potentiates behavioral responses to dopaminergic drugs in rats. Pharmacol Biochem Behav 46:35-139.
68. Villanueva HF, Arezo S, James JR, Rosecrans JA. 1992. A characterization of nicotine-induced tolerance: evidence of pharmacological tolerance in the rat. Behav Pharmacol 3:255-260.
69. Walter S, Kuschinsky K. 1989. Conditioning of nicotine effects on motility and behaviour in rats. Naunyn-Schmiedeberg Arch Pharmacol 339:208-213.
70. 14C into several rat tissues in vivo and in vitro. Toxicol Appl Pharmacol 12:560-567.